Lectus: Accessory virtues

Ion channel modulators are widely marketed to treat cardiovascular and other indications. However, small molecule ion channel modulators historically are associated with side effects related to poor ion channel selectivity. Lectus Therapeutics Ltd. believes its Leveraged Enabling Proteomics Technology for Ion Channel Screening (LEPTICS) will allow it to overcome this problem by identifying small molecule compounds that bind more specific targets.

Lectus (Bristol, U.K.) is using the technology to discover compounds for urinary incontinence and other smooth muscle disorders, including angina and hypertension, while partnering other indications...